Pharmacological Characterization of Dezocine, a Potent Analgesic Acting as a $\kappa$ Partial Agonist and $\mu$ Partial Agonist

Yu-Hua Wang$^1$, Jing-Rui Chai$^2$, Xue-Jun Xu$^2$, Ru-Feng Ye$^2$, Gui-Ying Zan$^2$, George Yun-Kun Liu$^3$, Jian-Dong Long$^2$, Yan Ma$^4$, Xiang Huang$^2$, Zhi-Chao Xiao$^2$, Hu Dong$^2$ & Yu-Jun Wang$^2$

Dezocine is becoming dominant in the China market for relieving moderate to severe pain. It is believed that Dezocine's clinical efficacy and little chance to provoke adverse events during the therapeutic process are mainly attributed to its partial agonist activity at the $\mu$ opioid receptor. In the present work, we comprehensively studied the pharmacological characterization of Dezocine and identified that the analgesic effect of Dezocine was a result of action at both the $\kappa$ and $\mu$ opioid receptors. We firstly found that Dezocine displayed preferential binding to $\mu$ opioid receptor over $\kappa$ and $\delta$ opioid receptors. Dezocine, on its own, weakly stimulated G protein activation in cells expressing $\kappa$ and $\mu$ receptors, but in the presence of full $\kappa$ agonist U50,488 H and $\mu$ agonist DAMGO, Dezocine inhibited U50,488H- and DAMGO-mediated G protein activation, indicating that Dezocine was a $\kappa$ partial agonist and $\mu$ partial agonist. Then the in intro results were verified by in vivo studies in mice. We observed that Dezocine-produced antinociception was significantly inhibited by $\kappa$ antagonist nor-BNI and $\mu$ antagonist $\beta$-FNA pretreatment, indicating that Dezocine-mediated antinociception was via both the $\kappa$ and $\mu$ opioid receptors. When co-administrating of Dezocine with U50,488 H or morphine, Dezocine was capable of inhibiting U50,488H- or morphine-induced antinociception. Finally, $\kappa$ receptor activation-associated side effect sedation was investigated. We found that Dezocine displayed limited sedative effect with a ceiling effecting at a moderate dose. Thus, our work led to a better understanding of the analgesic mechanism of action of Dezocine in vivo.

Morphine, fentanyl and all related opioid drugs used for relieving moderate and severe pain in clinic are agonists at $\mu$ opioid receptors$^{1,2}$. These prototypical $\mu$ agonists produced potent analgesia, and also mediated adverse effects including liability to addiction, respiratory depression, constipation and urinary retention, by action at $\mu$ opioid receptors$^3$. An approach to limiting the undesirable side effects, but still have therapeutic potential as potent analgesics is to develop compounds that possess mixed agonist-antagonist or partial agonist activities at different opioid receptors, since activation of the different opioid receptors may have synergistic effects or may produce fewer side effects than acting at a single target$^4$-$^7$. The well-known mixed agonist/antagonist analgesics include pentazocine, butorphanol, nalbuphine, buprenorphine and Dezocine$^1$-$^7$, among which, Dezocine, a synthesized bridged aminotetralin$^4$-$^8$-$^10$, currently is a prescribed painkiller in China for moderate to severe pain treatment. In 2016, sales of Dezocine reached more than $630$ million nationally, with occupying over 45% of the nation's opioid analgesics market.

Early studies demonstrated that Dezocine produced more potent or equipotent analgesia than morphine in rodents, primates and humans, due to its $\mu$ agonist (morphine-like) activity$^{10}$. The evidence came from both in vitro functional studies$^{11}$ and in vivo drug antinociceptive$^{12}$ and discriminative stimulus studies$^{13}$. Meanwhile, Dezocine exhibited certain $\mu$ antagonist activity as showing by the fact that Dezocine produced antagonism on morphine-induced loss of righting reflex, although Dezocine did not significantly precipitate withdrawal jumping.

1School of Pharmacy, Nanjing University of Chinese Medicine, Nanjing, 210046, China. 2Key Laboratory of Receptor Research, Shanghai Institute of Materia Medica and Collaborative Innovation Center for Brain Science, Chinese Academy of Science, Shanghai, 201203, China. 3Dublin Coffman High School, Dublin, OH, 43017, USA. 4School of Life Sciences, Shanghai University, Shanghai, 200444, China. Correspondence and requests for materials should be addressed to Y.-J.W. (email: yjwang@mail.simm.ac.cn)
syndrome in chronically morphine-treatment mice. Compared with opioid analgesics acting as \(\mu\) full agonists such as morphine, Dezocine has a safe and tolerable side-effects profile, including relatively low analgesic tolerance, lack of physical dependence capacity and limited respiratory depression. According to these observations, Dezocine seems to perform as a \(\mu\) partial agonist, which can explain its unique profile. Indeed, Liu with his colleagues recently characterized molecular targets for Dezocine and provided reliable evidence supporting that Dezocine acted as a \(\mu\) partial agonist. In addition to \(\mu\) opioid receptors, Dezocine also interacted with \(\kappa\) opioid receptors, however, the profile of Dezocine at \(\kappa\) receptors remained controversial. Due to its structurally related to Pentazocine, a \(\kappa\) agonist and \(\mu\) partial agonist, Dezocine was initially identified as a \(\kappa\) agonist. Subsequent studies from Gharagouzou et al. (2006) and Liu et al. (2014) by using \textit{in vitro} functional assay demonstrated that Dezocine acted as a \(\kappa\) antagonist. At present, \textit{in vivo} data regarding to its activity at \(\kappa\) opioid receptor is lacking. Whether Dezocine-induced analgesia was partially a result of action at \(\kappa\) receptor and \(\kappa\) receptor-associated side effects were unknown.

Thus, the present work was undertaken to comprehensively address the pharmacological properties of Dezocine. We found that Dezocine displayed preferential binding to \(\mu\) opioid receptor over \(\kappa\) and \(\delta\) opioid receptors, and acted as a \(\kappa\) partial agonist and \(\mu\) partial agonist, evaluated by functional \(\text{[^{35}S]}\text{GTP}\gamma\text{S}\) binding assay. In \textit{in vivo} studies, Dezocine produced more potent antinociception than morphine, which was via activation of both the \(\kappa\) and \(\mu\) opioid receptors. Dezocine was capable of inhibiting \(\kappa\) agonist- and \(\mu\) agonist-induced antinociception. In addition, Dezocine displayed limited sedative effects with a ceiling effecting at a moderate dose.

## Results

### Affinity, selectivity and efficacy of Dezocine.

Figure 1 depicts the structure of Dezocine. Competitive inhibition of \([^{3}H]\)ligands (\([^{3}H]\)U69593, \([^{3}H]\)DAMGO and \([^{3}H]\)DPDPE) binding to opioid receptors (\(\kappa\), \(\mu\), and \(\delta\)) by Dezocine was conducted to examine the binding affinities of Dezocine. As shown in Fig. 2A–C and Table 1, Dezocine had \(K_i\) values of 1.46 nM, 22.01 nM and 398.6 nM for \(\mu\), \(\kappa\), and \(\delta\) opioid receptors, respectively. The data indicated that Dezocine displayed preferential binding to \(\mu\) opioid receptors over \(\kappa\) and \(\delta\) opioid receptors.

To characterize the efficacy and potency of Dezocine, the \(\text{[^{35}S]}\text{GTP}\gamma\text{S}\) binding assay was conducted. As shown in Fig. 3A–C and Table 2, DAMGO and U50,488 H, as reference compounds, exhibited full agonist efficacy for G protein activation by \(\mu\) and \(\delta\) opioid receptors, but Dezocine-stimulated \(\text{[^{35}S]}\text{GTP}\gamma\text{S}\) binding assay. In \textit{in vivo} studies, Dezocine produced more potent antinociception than morphine, which was via activation of both the \(\kappa\) and \(\mu\) opioid receptors. Dezocine was capable of inhibiting \(\kappa\) agonist- and \(\mu\) agonist-induced antinociception. In addition, Dezocine displayed limited sedative effects with a ceiling effecting at a moderate dose.

### Antinociceptive effects of Dezocine.

The antinociceptive property of Dezocine was characterized in different acute pain models. In the hot-plate test, a bell-shaped dose-response curve was obtained with Dezocine (Fig. 5A). The maximal antinociceptive effect was around 60% at 7.5 mg/kg, and higher dose (10 mg/kg) was not able to further increase the antinociception. Thus, the estimated antinociceptive \(\text{ED}_{50}\) of Dezocine in the hot-plate test was not obtained. To improve thermal antinociceptive efficacy, different administration routes, i.e., s.c., or p.o. were carried out. However, whatever the route of administration, Dezocine produced maximal antinociception around 55% (Fig. 5B). A fast onset of action was observed at 5 min, and the consistent high (close to peak) antinociceptive response up to 1 h was observed (Fig. 5C).

In the abdominal constriction test, Dezocine produced a full-dose-response curve with an \(\text{ED}_{50}\) value of 0.2 mg/kg (Fig. 5D, Table 3), which was 4-fold more potent than morphine (\(\text{ED}_{50}: 0.8\) mg/kg, Table 3). In the formalin test, Dezocine also produced a full dose-response curve in both phase I and phase II, with \(\text{ED}_{50}\) values of 0.4 mg/kg (Fig. 5E, Table 3), which were approximately 13-fold more potent than morphine (\(\text{ED}_{50}: 5.1\) mg/kg) in the phase I and 9-fold more potent than morphine in the phase II (\(\text{ED}_{50}: 3.1\) mg/kg).

### Agonist properties of Dezocine.

Next, the agonist effect produced by Dezocine in the abdominal constriction test was determined by the use of selective antagonists. As shown in Fig. 6, one-way ANOVA assay revealed that the treatments induced significant changes [\(F(2,27) = 4.867, p < 0.05\)]. The following Tukey’s comparison test showed that \(\kappa\) antagonist nor-BNI (\(p < 0.05\)) and \(\mu\) antagonist β-FNA (\(p < 0.05\)) significantly
decreased Dezocine-produced antinociception, indicating that the antinociceptive action of Dezocine was mediated by both the \( \kappa \) and \( \mu \) opioid receptors.

**Antagonist properties of Dezocine.** Our *in vitro* data indicated that Dezocine exhibited partial agonist activity at \( \mu \) and \( \kappa \) opioid receptors, suggesting that Dezocine could act as a \( \kappa \) and \( \mu \) antagonist, in addition to its agonist activity. To assess the antagonist activity of Dezocine, Dezocine and \( \kappa \) agonist U50,488 H or \( \mu \) agonist morphine were administered concomitantly. As shown in Fig. 7A, Dezocine pretreatment did not inhibit U50,488 H-induced antinociception. However, in the presence of \( \mu \) antagonist \( \beta \)-FNA, Dezocine significantly decreased the antinociceptive effects produced by U50,488 H (\( p < 0.05 \), Fig. 7B). We further found Dezocine, at the dose of 0.05 mg/kg, significantly decreased the antinociceptive effects produced by 0.4 mg/kg morphine (\( p < 0.05 \)), but did not affect the action produced by 0.3 mg/kg morphine (Fig. 8). Co-administration of 0.125 mg/kg Dezocine and 0.3 mg/kg morphine produced higher antinociception than morphine used alone (\( p > 0.05 \), Fig. 8).

**Sedative side effect of Dezocine.** Activation of \( \kappa \) opioid receptors causes severe side effects of sedation, which is undesirable for therapeutic use. To study the sedative effects of Dezocine, the mice ability to maintain their position on an accelerating rotarod was detected. As shown in Fig. 9, animals were injected with various doses of Dezocine (2.5–25 mg/kg), then the rotarod test was conducted. Dezocine, at a dose of 5 mg/kg, produced significant sedation (\( p < 0.05 \)), when the dose increased (7.5 and 25 mg/kg), the sedative effect diminished. There was a trend that 2.5 mg/kg Dezocine caused sedation, but it did not reach significant difference (\( p = 0.0881 \)).

**Discussion**

Our *in vitro* binding studies indicated that Dezocine produced high affinity at \( \mu \) opioid receptor with \( K_i \) value of 1.46 nM, which was 15- and 273-fold selectivity for \( \mu \) over \( \kappa \) and \( \delta \) opioid receptors. These binding affinity results of Dezocine were consistent with the published data\(^{17,19} \). By using functional [\(^{35}\)S]GTP-\( \gamma \)S binding assay, we demonstrated that Dezocine acted as a \( \mu \) partial agonist, which was also consistent with the well-known low activity of Dezocine to stimulate \( \mu \) receptors\(^{8} \). We further demonstrated that Dezocine was a \( \kappa \) partial agonist, which was different from the existing literatures showing that Dezocine acted as a \( \kappa \) antagonist\(^{17,18} \). We found that Dezocine produced maximal stimulation of [\(^{35}\)S]GTP-\( \gamma \)S binding up to 33–45% mediated by \( \kappa \) receptors. Meanwhile, Dezocine also exhibited inhibitory effect on \( \kappa \) agonist U50,488 H-stimulated [\(^{35}\)S]GTP-\( \gamma \)S binding. Thus, Dezocine was termed by us as a \( \kappa \) partial agonist because, on its own, it had a lower intrinsic activity than full \( \kappa \) agonist U50,488 H, but in the presence of U50,488 H, it acted as a weak antagonist by preventing access to the \( \kappa \) receptor. Existing literature indicated that the functional action of Aripiprazole, a partial agonist at Dopamine D2 receptors, might vary among agonist, partial agonist or antagonist depending upon the level of receptor expression, function examined, and assessment assay applied\(^{20,21} \).

| Compounds | \( \mu \) binding affinity \( K_i \) (nM) | \( \delta \) binding affinity \( K_i \) (nM) | \( \kappa \) binding affinity \( K_i \) (nM) |
|-----------|-------------------------------|-------------------------------|-------------------------------|
| Dezocine  | 1.46 ± 0.10                   | 398.6 ± 43.25                 | 22.01 ± 1.52                  |
| DAMGO     | 2.30 ± 0.02                   | —                             | —                             |
| DPDPE     | —                             | 4.36 ± 0.69                   | —                             |
| U50,488 H | —                             | —                             | 0.91 ± 0.20                   |

Table 1. Affinity values (\( K_i \)) for the binding to human \( \kappa \)-, rat \( \mu \)-, or rat \( \delta \)-opioid receptors. Membranes were incubated with varying concentrations of ligands in the presence of 2.0 nM [\(^{3}\)H]DAMGO, 1.1 nM [\(^{3}\)H]DPDPE and 1.5 nM [\(^{3}\)H]U69593. Data are expressed as the mean ± SEM for at least three independent experiments performed in triplicate.
Table 2. Functional activity of Dezocine at human κ-, rat μ-, or rat δ-opioid receptors. Membranes were incubated with varying concentrations of ligands in the presence of 0.1 nM [35S]GTPγS. Data are expressed as the mean ± SEM for at least three independent experiments performed in triplicate. aNot tested because of low affinity at DOR. bLow stimulation at 10 μM. cNot applicable. dThe agonist efficacy at 10 μM.

Table 3. ED50 Values of the antinociception produced by Dezocine and Morphine. The antinociceptive ED50 values were calculated from data obtained at 15 min after drug administration. In parentheses are 95% confidence limits. a,bThe data of morphine associated with hot-plate test, abdominal constriction test and formalin test were cited from our previous data34,35.

Figure 3. Stimulation of [35S]GTPγS to κ, μ and δ opioid receptors by Dezocine and reference compounds. Each data point represents the mean ± SEM of at least three independent experiments conducted in triplicate. Emax and EC50 values are shown in Table 2.

Figure 4. Antagonism of U50,488 H and DAMGO-induced [35S]GTPγS binding by Dezocine. Dezocine, at a concentration of 10 nM or 10 μM, was co-incubated with DAMGO or U50,488 H. Each data point represents the mean ± SEM of at least three independent experiments conducted in triplicate. Ke values are shown in Table 2.
Considering that *in vitro* assay may not accurately reflect the action of Dezocine *in vivo*, the behavioral experiments in mice were conducted. In the abdominal constriction and formalin tests, we found that Dezocine produced full dose-response curves and displayed more potent antinociceptive response than morphine. In agreement, Dezocine was proved substantially more potent than morphine and pentazocine in the rodents and monkey4. In contrast to this sigmoid curve, in the hot plate test (55 °C), Dezocine-induced antinociception exhibited a bell-shaped dose-response curve. The similar bell-shaped dose-response curve was displayed in the antinociceptive action of pentazocine and buprenorphine22–26. Buprenorphine acted as κ antagonists27 and μ partial agonists23,24,28 and pentazocine acts as a κ agonist and μ partial agonist29. Thus, it seems that the plausible explanation for the observed ceiling effect on antinociception is that these compounds behave as μ partial agonists. The exact rationale for a ceiling effect of Dezocine-produced antinociception in the hot-plate test was unclear, but the possibility was suggested by data developed by the Lutfy group25, showing that the bell-shaped dose-response curve of buprenorphine was eliminated by the ORL-1 receptor antagonist and speculated that activation of ORL-1 receptors compromises the receptor-mediated antinociceptive action of buprenorphine. Shu et al. (2011) found that nor-BNI enhanced the antinociception by pentazocine and turned the later descending portion of

---

**Figure 5.** The antinociceptive effects of Dezocine evaluated by the hot plate test (A), abdominal constriction test (D) and formalin test (E). (B) The analgesic effects of Dezocine following different routes of administration. (C) Time courses for the effects of Dezocine in producing antinociception. After injected with various doses of Dezocine and the reference drug morphine, the antinociception was measured. ED50 values are shown in Table 3. Data are presented as mean ± SEM from at least 10 mice.

**Figure 6.** The Antinociceptive effects of Dezocine were mediated by κ and μ receptors in the abdominal constriction test. Mice were pretreated with 20 mg/kg nor-BNI and β-FNA for 24 h, then injected with 0.25 mg/kg Dezocine. Acetic acid solution was injected 15 min after drug administration. Data are presented as mean ± SEM from at least 10 mice. *p < 0.05 in comparison with Dezocine alone.
the bell-shaped dose-response curve into a sigmoid curve and proposed that activation of κ receptor compromised the μ receptor-mediated antinociception of pentazocine. Thus, it is possible that Dezocine activates other molecular targets, and compromises opioid receptor-mediated actions of Dezocine. Indeed, in addition to opioid receptors, Dezocine also targets amine transporter proteins.

**Figure 7.** Effects of Dezocine on κ agonist U50,488H-induced antinociception. (A) Dezocine did not affect U50,488H-produced antinociceptive effects. (B) In the presence of μ antagonist β-FNA, pretreatment with Dezocine significantly decreased the antinociceptive effects produced by U50,488 H. Mice were injected with U50,488 H and Dezocine with or without β-FNA. After 15 min, the antinociception was measured in the abdominal constriction test. Data are presented as mean ± SEM from at least 10 mice. *p < 0.05 in comparison with U50,488 H + β-FNA group.

**Figure 8.** Effects of Dezocine on μ agonist morphine-induced antinociception. Mice were injected with morphine with or without Dezocine. After 15 min, the antinociception was measured in the abdominal constriction test. Data are presented as mean ± SEM from at least 10 mice. *p < 0.05 in comparison with 0.3 mg/kg morphine, #p < 0.05 in comparison with 0.4 mg/kg morphine.

**Figure 9.** The sedative effects of Dezocine in rotorod test. Mice were injected with various doses of Dezocine, after 15 min, the mice were put on the rotorod apparatus, the time duration for each mice to fall off was recorded. Data are presented as mean ± SEM from at least 10 mice. *p < 0.05 in comparison with saline.
We further found that the antinociceptive action of Dezocine was inhibited by κ antagonist nor-BNI and μ antagonist β-FNA, supporting our in vitro conclusion that Dezocine had κ and μ agonist activity. It is believed that Dezocine’s clinical efficacy and little chance to provoke adverse events during the therapeutic process are mainly attributed to its partial agonist activity at the μ opioid receptors. However, we demonstrated that the antinociceptive response of Dezocine was a result of action at both the κ and μ opioid receptors. Liu et al. (2014) demonstrated that in addition to opioid receptors, Dezocine also targeted norepinephrine and serotonin reuptake. Wang et al. (2017) further found that Dezocine produced antihypersensitivity activity in neuropathic pain through its μ activation and norepinephrine reuptake inhibition (NRI). The activity of Dezocine at non-opioid sites in acute pain modulation was not investigated in the present work.

To assess the antagonist activity of Dezocine at the κ receptor in vivo, the animals were pretreated with Dezocine before giving a κ agonist U50,488 H. We noticed that Dezocine did not inhibit the antinociceptive effect of U50,488 H. A possible explanation for this finding was that Dezocine-suppressed U50,488 H action was compromised by its own μ agonist activity. Indeed, in the presence of μ agonist β-FNA, Dezocine exhibited κ antagonist activity as demonstrated by its ability to decrease U50,488H-induced antinociception. On the other hand, we found that 0.05 mg/kg Dezocine significantly inhibited agonist activity as demonstrated by its ability to decrease U50,488H-induced antinociception, indicating its μ antagonist activity. Whereas co-administration of 0.125 mg/kg Dezocine with morphine produced higher antinociception than morphine used alone. This phenomenon can also be rationalized as resulting from Dezocine-induced κ receptor activation. Thus, our results may explain the controversial findings within the literature concerning the benefit of Dezocine and other opioid analgesic drugs in combination. Dezocine, as a μ partial agonist, was able to antagonize morphine analgesia, but due to its κ agonist activity, combination of Dezocine and morphine might produce higher analgesic effects than morphine alone. The action of Dezocine may vary depend on the dosage used. The accurate interactions between Dezocine and morphine or other opioids need further investigation.

The partial agonist activity is generally believed to support it safety, such as buprenorphine displays a ceiling effect on μ receptor-mediated respiratory depression. Hence, we assume that Dezocine can produce lower κ receptor activation-associated sedative side effects. Indeed, in the present work, we found that Dezocine exhibited limited sedative effects with a ceiling effecting at 5 mg/kg. Moreover, attributed to the fact that the ED50 values of Dezocine-induced antinociception was around 0.2–0.4 mg/kg, the dose of Dezocine that produced sedative side effects (5 mg/kg) was much higher than those to produce antinociception. Thus, the partial agonist activity of Dezocine supports it unique property for clinical application with less side effects.

Taken together, Dezocine was demonstrated as a κ partial agonist and μ partial agonist. In mice model of acute pain, Dezocine-produced antinociception was mediated by both the κ and μ receptor activation. Dezocine displayed limited sedative effects with a ceiling effecting at a moderate dose. Combined with other opioid drugs, the action of Dezocine may vary depend on the dosage used.

**Methods**

**Drugs.** (±)-trans-U-50488 H (U50,488 H), [D-Ala2,N-Me-Phe4,Gly5-ol]-enkephalin (DAMGO) [D-Pen2,P-Cl-Phe4]Enkephalin (DPDPE), nor-binaltorphimine (nor-BNI), β-FNA, naloxone, GTP-S and GDP were obtained from Sigma-Aldrich (St. Louis, MO). [3H]DAMGO (51.5 Ci/mmol), [3H]DPDPE (57.4 Ci/mmol), [3H]U69593 (43.6 Ci/mmol) and [35S]GTP-γ-S (1250 Ci/mmol) were bought from Perkin Elmer.

**In vitro studies.** Cell culture. Chinese hamster ovary (CHO) cells stably expressing human κ-, rat μ, or rat δ opioid receptors were maintained in F12 medium (Gibco) with 10% fetal serum and 0.25 mg/ml (G418) (Roche). Cells were incubated in a humidified atmosphere consisting 95% air and 5% CO2 at 37°C, and were seeded in 10 cm dishes. Cells were collected when reached 85% confluence, and the cell membrane was prepared.

**Cell membrane preparation.** Cells were washed with phosphate buffer saline (PBS), detached by incubation with PBS containing 1 mM EDTA, and centrifuged at 1000 g for 10 min. The cell pellet was suspended and homogenized in ice-cold homogenization buffer (50 mM HEPES, 1 mM MgCl2, 1 mM EDTA, pH 7.4). After centrifugation at 40,000 g for 10 min (4°C), pellets were resuspended, homogenized and centrifuged again. The final pellets were resuspended in Tris–HCl buffer (50 mM, pH 7.4). Protein concentration was detected and the aliquots were stored at −80°C.

**Receptor binding assay.** Ligand binding assay was carried out according to our work. Competition inhibition of [3H]ligands binding opioid receptors by Dezocine, U50,488 H, DAMGO or DPDPE was performed in the absence or presence at various concentration of each compound. The binding assay was performed in Tris–HCl buffer (50 mM, pH 7.4) at 37°C for 30 min in triplicate in a final volume of 0.5 ml containing 30 μg of membrane protein and [3H]ligands ([3H]U69593 1.5 nM; [3H]DAMGO 2.0 nM; [3H]DPDPE 1.1 nM). Naloxone (10 μM) was used to define nonspecific binding. Bound and free [3H]ligands were separated by filtration under reduced pressure with GF/B filters (Whatman). Radioactivity was determined by liquid scintillation counter (Beckman LS6500).

[35S]GTP-γ-S binding assay. [35S]GTP-γ-S binding assay was carried out according to our work. Briefly, membranes (15 μg) were incubated with 0.1 nM [35S]GTP-γ-S in reaction buffer (50 mM Tris-HCl, 1 mM EDTA, 5 mM MgCl2, 100 mM NaCl, pH 7.4) and 40 μM GDP at 30°C for 1 h in the presence of increasing concentrations of Dezocine, U50,488 H, DAMGO or DPDPE. Nonradioactive GTP-γ-S (10 μM) was used to define nonspecific binding. Radioactivity was determined by liquid scintillation counter (Beckman LS6500). The percentage of stimulated [35S]GTP-γ-S binding was calculated as 100 × (cpm sample − cpm nonspecific)/cpm basal − cpm nonspecific.
The potency of an antagonist is defined by its $K_e$ (equilibrium dissociation constant) value, as determined by the “single” dose method. The agonists (U50, 488H and DAMGO) dose-response curves were generated in the absence and presence of Dezocine. The $K_e$ value is calculated according to the equation:

$$\frac{[\text{test drug}]/(EC_{50-2}/EC_{50-1} - 1)}{\text{time of drug}}$$

where $EC_{50-2}$ value is the $EC_{50}$ value in the presence of the test drug and $EC_{50-1}$ is the value in the absence of the test drug.

**In vivo studies.** Animals. Kunming strain male and female mice weighing 20 to 24 g were obtained from the Laboratory Animal Center, Chinese Academy of Sciences (Shanghai, China). Mice were housed in groups in a room maintained in a 12/12 h light/dark cycle in a temperature controlled environment with free access to food and water. All research protocols were approved by the Animal Care and Use Committee of Shanghai Institute of Materia Medica, Chinese Academy of Sciences. All experimental procedures were in strict accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals.

**Antinociceptive tests.** *Hot plate test.* Hot plate test was performed according to the method described previously. Briefly, mice were placed on a 5°C heated surface, the latency to licking or jumping was recorded. The cut-off time of 60 s was used to minimize tissue damage. Before formal study, the nociceptive response of each mouse was measured three times, and the mean of the 2nd and 3rd responses was used as pre-drug latency. The mouse not responding within 20 s was excluded. The percentage antinociception was calculated as $100 \times \frac{(\text{test latency} - \text{predrug latency})}{(\text{cut-off time} - \text{predrug latency})}$.

**Abdominal constriction test.** The abdominal constriction test was conducted according to our previous work. An abdominal constriction was defined as a wave of contraction of the abdominal musculature followed by extension of the hind limbs after injected with 0.6% of acetic acid (10 ml/kg body weight, i.p.). The number of abdominal constriction was counted for 15 min after acetic acid administration. Percentage of analgesia was expressed as $100 \times \frac{(\text{No. of control abdominal constriction} - \text{No. of test abdominal constriction})}{\text{No. of control abdominal constriction}}$.

**Formalin test.** The formalin test was performed according to our previous work. In brief, the amount of time that mice spent licking or flinching the injected hind paw was recorded after injected with 20μl 1.0% formalin at the plantar surface of the right hind paw. The mice were observed from 60 min. The first 10 min was recorded as the phase I, and the rest of time was recorded as phase II. Percentage of analgesia was calculated as $100 \times \frac{(\text{time of control} - \text{time of drug})}{\text{time of control}}$.

**Agonist effect of Dezocine.** To define the agonist profile of Dezocine, mice were pretreated with selective $k$ antagonist nor-BNI (20 mg/kg, i.p., $\mu$ antagonist 3-FNA (20 mg/kg, i.p., $\mu$ antagonist 3-FNA (20 mg/kg, i.p., $\mu$ antagonist 3-FNA (20 mg/kg, i.p., 24 h), $\beta$-FNA (20 mg/kg, i.p., $\beta$-FNA (20 mg/kg, i.p., $\beta$-FNA (20 mg/kg, i.p., saline$^{31,34,35}$, then mice were administrated with Dezocine. After 15 min, the antinociceptive effect was assessed.

**Antagonist effect of Dezocine.** To define the $k$ antagonist profile of Dezocine, mice were pretreated with various doses of Dezocine or saline. 5 min later, the mice were administrated with $k$ agonist U50,488 H (1.2 mg/kg, i.p.) After 15 min, the antinociceptive effect was assessed. To avoid Dezocine's $\mu$ agonist activity contributing to its antinociception, mice were pretreated with $\mu$ antagonist 3-FNA before Dezocine and U50,488 H co-administration. The $\mu$ antagonist effect of Dezocine was also determined by pretreatment with Dezocine followed by $\mu$ agonist morphine injection. After 15 min, the antinociceptive effect was assessed.

**Rotorod test.** The test was conducted in mice according to the method described previously with slight modification. In brief, mice was individually trained to maintain their position on a rotorod for 120 s or more, and the mice falling off within 120 s were excluded. 15 min after Dezocine injection, mice were put on the rotorod apparatus, the time duration for each mouse to fall off was recorded.

**Statistical Analysis.** Curve-fitting analysis was performed using GraphPad Prism 6.0 software. Data represents the mean ± SEM of at least three separate experiments. Statistical significance was determined by one-way ANOVA followed by post hoc comparison using Tukey's tests. When only two groups were compared, statistical significance was determined by unpaired student's $t$ test.

**Data Availability Statement** All data generated or analyzed during this study are included in this published article.

**References**

1. Spetea, M., Asim, M. F., Wolber, G. & Schmidhammer, H. The micro opioid receptor and ligands acting at the micro opioid receptor, as therapeutics and potential therapeutics. *Curr. Pharm. Des.* 19, 7415–7434 (2013).
2. Matthes, H. W. *et al.* Loss of morphine-induced analgesia, reward effect and withdrawal symptoms in mice lacking the mu-opioid-receptor gene. *Nature* 383, 819–823 (1996).
3. Owusu, O. A., Hamadeh, I. & Smith, M. Review of Opioid Pharmacogenetics and Considerations for Pain Management. *Pharmacotherapy* 37, 1105–1121 (2017).
4. O’Brien, J. J. & Benfield, P. Dezocine. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy. *Drugs* 38, 226–248 (1989).
5. Schiller, P. W. Bi- or multifunctional opioid peptide drugs. *Life Sci.* 86, 598–603 (2010).
6. Morphy, R. & Rankovic, Z. Designed multiple ligands. An emerging drug discovery paradigm. *J. Med. Chem.* 48, 6523–6543 (2005).

7. Hoskin, P. J. & Hanks, G. W. Opioid agonist-antagonist drugs in acute and chronic pain states. *Drugs* 41, 326–344 (1991).

8. Fragen, R. J. & Caldwell, N. Comparison of dezocine (WY 16, 225) and meperidine as postoperative analgesics. *Anesth. Analg.* 57, 563–566 (1978).

9. Jasinski, D. R. & Preston, K. L. Assessment of dezocine for morphine-like subjective effects and miosis. *Clin. Pharmacol. Ther.* 38, 544–548 (1985).

10. Malis, J. L., Rosenthal, M. E. & Gluckman, M. I. Animal pharmacology of Wy-16,225, a new analgesic agent. *J. Pharmacol. Exp. Ther.* 194, 488–498 (1975).

11. Ghargazolou, P., Demirici, H., David, C. J. & Lameh, J. Activity of opioid ligands in cells expressing cloned mu opioid receptors. *BMC Pharmacol.* 3, 1 (2003).

12. Wang, Y. X., Mao, X. F., Li, T. F., Gong, N. & Zhang, M. Z. Dezocine exhibits antihypersensitivity activities in neuropathy through spinal mu-opioid receptor activation and norepinephrine reuptake inhibition. *Sci. Rep.* 7, 43137 (2017).

13. Schaefer, G. J. & Holtzman, S. G. Morphine-like stimulus effects in the monkey: opioids with antagonist properties. *Pharmacol. Biochem. Behav.* 14, 241–245 (1981).

14. Wu, F. X., Pan, R. R., Yu, W. F. & Liu, R. The Anti-Nociception Effect of Dezocine in a Rat Neuropathic Pain Model. *Trans. Peripher. Pain Med.* 1, 5–8 (2014).

15. Gal, T. J. & DiFazio, C. A. Ventilatory and analgesic effects of dezocine in humans. *Anesthesiology* 61, 716–722 (1984).

16. Romagnoli, A. & Keats, A. S. Ceiling respiratory depression by dezocine. *Anesthesiology* 35, 367–373 (1984).

17. Liu, R., Huang, X. P., Yeliseev, A., Xi, J. & Roth, B. L. Novel molecular targets of dezocine and their clinical implications. *Anesthesiology* 120, 714–723 (2014).

18. Ghargazolou, P., Hashemi, E., DeLorey, T. M., Clark, J. D. & Lameh, J. Pharmacological profiles of opioid ligands at kappa opioid receptors. *BMC Pharmacol.* 6, 3 (2006).

19. Chen, J. C., Smith, E. R., Cahill, M., Cohen, R. & Fishman, J. B. The opioid receptor binding of dezocine, morphine, fentanyl, butorphanol and nalbuphine. *Life Sci.* 52, 389–396 (1993).

20. Shapiro, D. A. et al. Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology. *Neuropsychopharmacology* 28, 1400–1411 (2003).

21. Lawler, C. P. et al. Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes. *Neuropsychopharmacology* 20, 612–627 (1999).

22. Cowan, A., Lewis, J. W. & Macfarlane, I. R. Agonist and antagonist properties of buprenorphine, a new antinociceptive agent. *Br. J. Pharmacol.* 60, 537–545 (1977).

23. Lizasoain, I., Leza, J. C. & Lorenzo, P. Buprenorphine: bell-shaped dose-response curve for its antagonist effects. *Gen. Pharmacol.* 22, 297–300 (1991).

24. Dum, J., Blasig, J. & Herz, A. Buprenorphine: demonstration of physical dependence liability. *Anesthesiology* 70, 293–300 (1989).

25. Lutfy, K. *et al.* Interactions of the novel antagonist aripiprazole (OR-121) with dopamine and serotonin receptor subtypes. *Neuropsychopharmacology* 28, 1400–1411 (2003).

26. Shu, H. et al. Pentazocine-induced antinociception is mediated mainly by mu-opioid receptors and compromised by kappa-opioid receptors in mice. *J. Pharmacol. Exp. Ther.* 338, 579–587 (2011).

27. Leander, J. D. Buprenorphine is a potent kappa opioi receptor antagonist in pigeons and mice. *Eur. J. Pharmacol.* 151, 457–461 (1988).

28. Cowan, A., Doxey, J. C. & Harry, E. The animal pharmacology of buprenorphine, an oripavine analgesic agent. *Br. J. Pharmacol.* 60, 547–554 (1977).

29. Archer, S., Albertson, N. F., Harris, L. S., Pierson, A. K. & Bird, J. G. Pentazocine. Strong analgesics and analgesic antagonists in the benzomorphan series. *J. Med. Chem.* 7, 123–127 (1964).

30. Jacobs, A. M. & Younghood, F. Opioid receptor affinity for agonist-antagonist analgesics. *J. Am. Podiatr. Med. Assoc.* 82, 520–524 (1992).

31. Wang, Y. J. *et al.* Pharmacological characterization of ATTPM [(–)-3-aminothiazolol[5,4-b]-N-cyclopropylmethylmorphinan hydrochloride], a novel mixed kappa-agonist and mu-agonist/-antagonist that attenuates morphine antinociceptive tolerance and heroin self-administration behavior. *J. Pharmacol. Exp. Ther.* 329, 306–313 (2009).

32. Li, N. N. *et al.* Dezocine Antagonizes Morphine Analgesia upon Simultaneous Administration in Rodent Models of Acute Nociception. *Pain Physician* 20, E401–E409 (2017).

33. Morgan, D., Cook, C. D., Smith, M. A. & Picker, M. J. An examination of the interactions between the antinociceptive effects of morphine and various mu-opioids: the role of intrinsic efficacy and stimulus intensity. *Anesth. Analg.* 105, 407–413 (2007).

34. Zhao, G. et al. L-PK-26, a novel kappa-opioid receptor agonist with potent antinociceptive effects and low dependence potential. *J. Pharmacol. Exp. Ther.* 358, 306–311 (2008).

35. Zhang, L. S. *et al.* Novel kappa-opioid receptor agonist MB-1C-OH produces potent analgesia with less depression and sedation. *Acta Pharmacol. Sin.* 36, 565–571 (2015).

36. Kosteritz, H. W. & Watt, A. J. Kinetic parameters of narcotic agonists and antagonists, with particular reference to N-allylnormorphan (naloxone). *Br. J. Pharmacol. Chemother.* 33, 266–276 (1968).

37. Ananthan, S. *et al.* 14-Alkoxo- and 14-acetoxypropydromorphinans: mu agonist/delta antagonist opioid analogues with diminished tolerance and dependence side effects. *J. Med. Chem.* 55, 8350–8363 (2012).

38. Kajiwara, M. *et al.* Agonist and antagonist actions of buprenorphine on three types of opioid receptor in isolated preparations. *Jpn. J. Pharmacol.* 40, 95–101 (1986).

Acknowledgements

The authors would like to thank Yangzi River Pharmaceuticals Group (Taizhou, Jiangsu, China) for providing Dezocine. This work was supported by grants from the National Natural Foundation of China 81773710 (Y.-J. W.), and from the Youth Innovation Promotion Association of the Chinese Academy of Sciences 2017334 (Y.-J. W).

Author Contributions

Y.-H.W., J.-R.C., X.-J.X., R.-F.Y., G.-Y.Z., G.Y.L., J.-D.L., M.Y. and Y.-J.W. conducted the experiment and collected data. Y.-J.W., Y.-H.W., J.-R.C. and X.-J.X. analyzed the data. Y.-J.W., X.H., Z.-C.X. and H.D. designed the study. Y.-J.W. prepared the manuscript.

Additional Information

Competing Interests: The authors declare no competing interests.

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
